Home Featured Page 251

Featured

Latest

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development,...

Webinar with Tim Cools of Psychedelic Experience

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged...

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston...

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

The Chopra Foundation and MindMed Enter Into Letter of Intent to...

Cybin Granted IRB Approval for Phase II Clinical Trials of its...

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

1...250251252...301 Page 251 of 301

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots...

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development,...

Webinar with Tim Cools of Psychedelic Experience

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged...

What Is Sacred Reciprocity?

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston...

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

The Chopra Foundation and MindMed Enter Into Letter of Intent to...

Cybin Granted IRB Approval for Phase II Clinical Trials of its...

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

EDITOR PICKS

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots...

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY